Products & Services · Intangibles, net

AstraZeneca milestone — Intangibles, net

Insmed AstraZeneca milestone — Intangibles, net decreased by 1.9% to $43.23M in Q1 2026 compared to the prior quarter.

Analysis

StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ4 2024
Last reportedQ1 2026
Rolls up toIntangibles (Net)

How to read this metric

An increase indicates successful achievement of development or regulatory milestones leading to asset capitalization, while a decrease reflects ongoing amortization or potential impairment.

Detailed definition

This represents the net carrying value of intangible assets acquired through milestone-based licensing or collaboration...

Peer comparison

Comparable to capitalized in-process research and development (IPR&D) or acquired intangible assets reported by other biopharmaceutical firms following licensing deals.

Metric ID: insm_segment_astrazeneca_milestone_intangibles_net

Historical Data

4 periods
 Q4 '24Q3 '25Q4 '25Q1 '26
Value$0.00$29.73M$44.05M$43.23M
QoQ Change——+48.2%-1.9%
Range$0.00 – $44.05M

Similar Metrics at Other Companies

Biogen logo
BiogenBIIBView metric
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTXView metric
Biogen logo
BiogenBIIBView metric
Viatris logo
ViatrisVTRSView metric
Agilent Technologies logo
Agilent TechnologiesAView metric
Biogen logo
BiogenBIIBView metric

Frequently Asked Questions

What is Insmed's astrazeneca milestone — intangibles, net?
Insmed (INSM) reported astrazeneca milestone — intangibles, net of $43.23M in Q1 2026.
What does astrazeneca milestone — intangibles, net mean?
The current net book value of intangible assets acquired through milestone payments to AstraZeneca.